retatrutide availability south africa Retatrutide: The New Triple-Agonist Weight Loss Treatment Retatrutide Weight Loss Treatment Explained
Description
As of March 29, 2026 , retatrutide remains investigational , not FDA approved
When retatrutide continuously activates GLP-1 receptors on sensory neurons, those neurons can become "trained" to fire more easily, lowering the threshold for what triggers a sensory response
European Journal of Biochemistry
However, some people may abuse it to lose weight, as weight loss can occur with Vyvanse use, says Michael McGrath, MD, board-certified psychiatrist and chief clinical officer at The Ohana Hawaii
Can I switch from phentermine to a GLP-1 medication
How Do I Know if GLP-1 is Working
